Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

GenSight Biologics S.A. - Filing #2810901

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	3	—	—	—	—	—	—	—	—	—	—
Reserve of exchange differences on translation	—	—	—	33,000 EUR	—	—	73,000 EUR	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	—	—	—	2,603,000 EUR	—	—	2,994,000 EUR	—	—	—	—	—
Current assets	—	—	—	6,529,000 EUR	—	—	22,947,000 EUR	—	—	—	—	—
Non-current liabilities	—	—	—	14,543,000 EUR	—	—	26,577,000 EUR	—	—	—	—	—
Current liabilities	—	—	—	25,290,000 EUR	—	—	14,642,000 EUR	—	—	—	—	—
Revenue	—	1,267,000 EUR	—	—	—	—	—	—	—	—	2,582,000 EUR	—
Profit (loss)	— EUR	26,220,000 EUR	26,220,000 EUR	—	— EUR	— EUR	—	— EUR	— EUR	27,625,000 EUR	27,625,000 EUR	— EUR
Comprehensive income	0 EUR	26,111,000 EUR	26,220,000 EUR	—	0 EUR	109,000 EUR	—	124,000 EUR	0 EUR	27,625,000 EUR	27,748,000 EUR	0 EUR